Background: Due to the high mortality rates from gallbladder carcinoma in Chile, we conducted a phase II trial to test the efficacy and safety of gemcitabine in patients with locally advanced or metastatic gallbladder carcinoma.
Introduction
Carcinoma of the bile tract is usually a rare disease, accounting for < 1% of deaths from cancer in the United States annually [1] . In some areas of Latin America, however, incidences of this disease are high. In Chile, bile tract carcinoma, specifically gallbladder carcinoma, is the leading cause of death from malignant neoplasms in women [2] . Unfortunately, in the last 20 years, there has been a significant increase in mortality from this disease in Chile -from 5.1/100,000 habitants in 1970 to 18/100,000 in 1996, probably due to a decrease in the number of cholecistectomies done in between 1973 and 1990 .
The most effective, although seldom curative, therapy for carcinoma of the gallbladder is the resection of the primary tumor and areas of local extension. Detection of the disease is difficult; in most cases, patients are found to be in the late stages of the disease at the time of diagnosis. In Chile, the average survival time for patients with advanced, non-resectable disease is only 10 weeks (range 4 to 14 weeks) [3] .
Few trials have been conducted to evaluate chemotherapy in patients with locally advanced or metastatic gallbladder carcinoma. In these trials, which assessed a very small number of patients, tumor response was uncommon and usually brief in duration. For singleagent systemic chemotherapy, objective response rates were 10% for mitomycin C and 11% for 5-flourouracil (5-FU) [4, 5] . Response rates for 5-FU-based combination systemic chemotherapy were 5% for 5-FU plus methyl-CCNU (lomustine) and 31% for FAM (5-FU plus adriamycin plus mitomycin C) [4, 6] .
Until 1995, 5-FU was used alone or in combination with leucovorin, and it achieved response rates of 26% [7] . Based on clinical data demonstrating the effectiveness of gemcitabine in pancreatic cancer [8] , and because the gallbladder shares a common embryological origin with the exocrine pancreas, we conducted a phase II trial to evaluate the response and toxicity of gemcitabine in patients with locally advanced or metastatic gallbladder carcinoma.
Patients and methods

Inclusion criteria
Eligibility criteria included histologically confirmed adenocarcinoma of the gallbladder with evidence of metastatic disease or unresectable local recurrence and no previous chemotherapy. Patients had lo have measurable disease on a computed tomography (CT) scan, a Karnofsky performance status (PS) < 3. age < 75 years, an adequate blood count (white blood cell count > 4000/ml and platelets > 100.000/ml). no signs of renal or hepatic failure (serum creatinine < 135 umol/l: prothrombin time > 75%), and no other malignancy. This study was conducted according to the ethical principles stated in ihe latest version of the Helsinki Declaration, and the applicable guidelines for good clinical practice (GPC). Each patient gave written informed consent
Baseline and treatment assessments
Patients received gemcitubine 1000 mg/m 2 over 30 minutes weekly for three weeks followed by a week of rest in an ambulatory setting. Cycles were repeated every four weeks. Treatment continued until disease progression or intolerable toxicily was observed, or patients elected to withdraw from the trial. Pre-treatment evaluation included a complete physical examination, an abdominal ultrasound, an abdominal CT scan, and a thoracic CTscan for patients with lung metastases. Hepatic enzyme levels were obtained before each cycle. Complete blood and platelet counts were performed every two weeks to assess hematological toxicity.
Tumor size was measured by CT scan, and tumor response was assessed every eight weeks after the start of the chemotherapy. No extramural review of response was carried out. Toxicity and tumor response were classified using standard WHO criteria. Duration of response was defined as the period between the onset of response and the onset of progressive disease. Survival was calculated from the start of chemotherapy until death using the Kaplan-Meier method. Pain and analgesic requirements were assessed every two weeks.
Results
Patient characteristics
From January 1998 to February 2000, 26 patients (9 male, 17 female) with a median age of 55.5 years (range 37-70) were consecutively enrolled in this phase II study. Main baseline patient characteristics are summarized in Table 1 .
Efficacy
One patient showing clinical improvement discontinued the study due to religious beliefs before the first tumor assessment and was not included in the evaluation of response. Another patient did not undergo a radiological evaluation, but clinically presented a progression of disease (PD) and was included in the analysis as a PD. Among the 25 patients, nine went into partial remission, for an overall response rate of 36% (95% CI: 17.1% to 57.9%). In six (24%) patients the disease was stable, and in 10 (40%) it was progressive. The median duration of response was 21.3 weeks and median survival time was 30.0 weeks (range 7 -80+). One-year survival rate was 33%. The Kaplan-Meier overall survival curve is provided in Figure 1 .
One partial responder, after nine courses of gemcitabine, was treated with surgery followed by chemotherapy plus radiation. She achieved a complete remission and remains in good health at the time of writing (one year).
For the 23 patients with baseline analgesic measurements, 11 (47.8%) had decrease analgesic consumption, and 12 (52.1%) maintained analgesic consumption during the trial.
Toxicity
All 26 patients were evaluable for toxicity. Patients received a median of 4.2 cycles (range 1-10). Hematological toxicities were generally mild ( (15.4%) patients had grade 3-4 neutropenia and 1 (3.8%) had grade 3-4 neutropenia. Two (7.7%) patients had grade 2 thrombocytopenia. Nine (34.6%) patients had grade 1-2 nausea/vomiting. No patients required dose adjustments and all continued to receive full treatment. There were no cases of febrile neutropenia or toxic deaths.
Discussion
Our study of 25 evaluable patients with advanced or metastatic gallbladder cancer is the first and largest study in which gallbladder tumors were treated with a uniform chemotherapeutic regime. This study produced promising results, including a 36% response rate, a median survival of 30.0 weeks and one-year survival rate of 33%. Treatment-related toxicity was mild, did not cause treatment to be discontinued and was not radically different from the toxicity observed in other types of tumors with the same treatment schedule [8, 9] . Several studies have tested single-agent and combination chemotherapy in gallbladder or bile-duct cancer. Monochemotherapy yielded disappointing results, with objective response rates ranging from 5% to 20%. Mitomycin C, which has seemed relatively active in the past, produced three partial remissions, for an overall response rate of 10% [5] . Paclitaxel for the treatment of bile-tract carcinoma also gave poor results; no complete or partial responses were noted in 13 patients, although two patients showed minor responses [10] .
Two phase II, randomized studies compared 5-FU alone to polychemotherapy. In the first study, patients were divided randomly into groups taking 5-FU alone, 5-FU plus streptozotocin or 5-FU plus methyl CCNU [5] , The comparison did not demonstrate an advantage for the polychemotherapy, which increased toxicity without clear benefit in terms of response. The second randomized trial produced comparable results, disproving the hypothesis that the combination of 5-FU, doxorubicin, and mitomycin C is superior to 5-FU alone [11] .
Two recent phase II studies yielded no responses; one used a combination of 5-FU, epirubicin, and methotrexate and the other 5-FU+LV, cyclophosphamide [12, 13] , but four other recent phase II studies have shown more promising results. The first study evaluated the combination of 5-FU and subcutaneous recombinant human interferon-a-2b in patients with measurable cancer of the bile tract [14] . Of the 32 evaluable patients in this study, the objective response rate was 34% and the median survival time was 12 months. A second phase II study investigated the efficacy of combined low-dose 5-FU continuous infusion with epirubicin and cisplatin (ECF) in patients with hepatobile tumors [15] . Eight (40%) of the 20 evaluable patients responded; the median duration of response was 10 months, and the median survival time was 11 months. The regimen was relatively well tolerated, with grade 3-4 leukopenia and thrombocytopenia in 16% and 19% of the patients, respectively; grade 3 alopecia was observed in 31% of the patients. A third study utilized 5-FU 1 g/m 2 as a continuous intravenous infusion over five days with cisplatin 100 mg/m 2 on day 2, every four weeks, to treat patients with advanced bile-tract carcinoma [16] . Of 25 evaluable patients, six had a partial remission, for an overall response rate of 24%. Grade 3-4 neutropenia or thrombocytopenia was observed in 10 patients. The median survival time was 10 months. The fourth trial also used carboplatin 300 mg/m 2 on day 1, and 5-FU 400 mg/m 2 with leucovorin 25 mg/m 2 on days 1-4. every four weeks, to treat patients with advanced bile tract carcinoma [17] . Median survival was five months. There was one complete response and two patients went into partial remission, for an overall response rate of 21%, but none of the four patients with gallbladder carcinoma responded.
These recent optimistic data are supported by the results of the only phase 3 study performed in this setting. Glimelius et al. [18] randomized 90 patients, 43 with pancreatic and 37 with bile cancer, to either best supportive care plus sequential 5-FU/leucovorin combined with etoposide or to best supportive care alone; elderly and poor-performance-status patients received the same chemotherapeutic regimen without etoposide. More patients in the chemotherapy group (36%, 17 of 49) had an improved or prolonged quality of life compared to those in the best supportive care group (10%, 4 of 41, P < 0.01). Additionally, the quality-adjusted survival time was longer for patients in the group receiving chemotherapy (median of 4 vs. 1 month, P < 0.01). However, when only the patients with bile-tract cancer were considered, these results were no longer statistically significant.
In two reported cases [19, 20] , patients with gallbladder cancer were resistant to 5-FU but responsive to gemcitabine. One of these patients [19] was treated with surgery followed by chemotherapy plus radiation. Upon relapse, she was treated with 5-FU and leucovorin, without significant effects. She then received 5-FU continuous infusion therapy, but demonstrated progression of disease. She was then treated with the same schedule of gemcitabine, which enabled her to achieve a partial response, followed by stabilization of the disease. She survived 14 months. During treatment, the patient continued working and experienced few adverse symptoms. Such a long survival time is seldom seen in this disease. Of special note is the fact that this response occurred after three prior regimes had failed.
In our study, one patient, who had extensive locoregional disease after a partial surgical resection, had a slow but constant response to gemcitabine. After nine months of treatment we decided to perform a second operation in which a small node was removed. Thereafter, she was treated with chemoradiotherapy, and after a 12-month follow-up, she remains disease-free. For the complete group in our study, the median survival of 30 weeks is superior to the three months historically observed in Chile [3] , and to the four months reported in our study of 5-FU/leucovorin [7] .
Because of the high mortality from gallbladder carcinoma in Chile, we urgently need to develop new treat-merit strategies, and gemcitabine appears to be worthy of clinical research. As results of our study indicate, gemcitabine is an active chemotherapy regimen in metastatic or inoperable gallbladder carcinoma, with a manageable toxicity profile. Based on these results, we recommend combining gemcitabine with other drugs, such as cisplatin or 5-FU, or with radiation (using similar regimes to those tested in pancreatic carcinoma), as well as testing gemcitabine as an adjuvant treatment for completely resected patients.
